Finasteride: an effective therapeutic for benign prostatic hyperplasia related gross hematuria in patients receiving anticoagulant.
- Author:
Yun-Hua LIN
1
;
Yong-Guang JIANG
;
Ming-Chuan LI
;
Tao PENG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Anticoagulants; therapeutic use; Fibrinolytic Agents; therapeutic use; Finasteride; therapeutic use; Follow-Up Studies; Hematuria; drug therapy; etiology; Humans; Male; Middle Aged; Prostatic Hyperplasia; complications; drug therapy; Treatment Outcome
- From: National Journal of Andrology 2009;15(1):31-33
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of finasteride on benign prostatic hyperplasia (BPH) related gross hematuria in patients receiving anticoagulant.
METHODSA total of 105 patients with BPH related gross hematuria were divided into an anticoagulant group (n = 81), treated with combined therapy of anticoagulants and finasteride, and a control group (n = 24), given finasteride only at 5 mg daily. The therapeutic effects were compared by a 6-month follow-up.
RESULTSIn the anticoagulant group, gross hematuria was cured in 52 patients (64.2%), taking an average time of 3.9 weeks (1-6 weeks), and improved in 12 patients (14.8%), as compared with 16 patients cured (66.7%), 3.2 weeks taken (1-5 weeks), and 4 patients improved (16.7%) in the control group. The mean time taken to resolve hematuria was longer in the former (P < 0.05). But the cure rates had no significant differences either between the two groups or among the subgroups receiving different anticoagulants.
CONCLUSIONFinasteride is an effective therapeutic for BPH related hematuria in patients receiving different anticoagulants. It makes no significant differences in cure and effectiveness rates between patients treated with and without anticoagulant, but takes an average of longer time to resolve hematuria in patients receiving anticoagulant.
